Lexicon Pharmaceuticals LXRX Product — Net product and licensing revenue

Other product segments

Similar metrics at other companies

XER

XERSProduct revenue, net — Product revenue, net

$82.45M+42.6%

CRNXProduct revenue, net — Total Revenue

$10.31M—

AGIOProduct revenue, net — Total Revenue

$20.75M+138%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

Questions, answered.

What is Lexicon Pharmaceuticals's product — net product and licensing revenue?

Lexicon Pharmaceuticals (LXRX) reported product — net product and licensing revenue of $1.09M in Q1 2026.

How has Lexicon Pharmaceuticals's product — net product and licensing revenue changed year-over-year?

Lexicon Pharmaceuticals's product — net product and licensing revenue decreased by 13.6% year-over-year, from $1.26M to $1.09M.

What is the long-term trend for Lexicon Pharmaceuticals's product — net product and licensing revenue?

Over 2 years (2023 to 2025), Lexicon Pharmaceuticals's product — net product and licensing revenue has grown at a 104.6% compound annual growth rate (CAGR), from $1.11M to $4.65M.

What does product — net product and licensing revenue mean?

This metric represents the total revenue generated from the sale of pharmaceutical products and associated licensing agreements within the company's primary product segment. It reflects the commercial success and market adoption of the company's drug portfolio after accounting for returns, allowances, and rebates. Monitoring this figure is essential for evaluating the company's transition from a research-focused entity to a commercial-stage biopharmaceutical business.